CYP19A1 and breast carcinoma: Endocrine therapies for ER+ breast cancer include selective ER modulators (SERMs) such as tamoxifen, aromatase inhibitors (AIs) such as anastrozole, ovarian function suspension (OFS) such as goserelin and selective ER downregulators (SERDs) such as fulvestrant.